FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Kerbel

Research Profile

Living Beings

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Drug Resistance, Neoplasm

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Margarita Todorova; Vlad Agache; Branson Chen; Kullervo Hynynen; Raffi Karshafian; Robert S Kerbel; Shan Man; Omid Mortazavi; David E Goertz
Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles.
Eric Guerin; Shan Man; Ping Xu; Robert S Kerbel
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Christina Hackl; Shan Man; Chloe Milsom; Ping Xu; Giulio Francia; Robert S Kerbel
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Kerbel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Margarita Todorova; Vlad Agache; Branson Chen; Kullervo Hynynen; Raffi Karshafian; Robert S Kerbel; Shan Man; Omid Mortazavi; David E Goertz
Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles.
International journal of cancer. Journal international du cancer 2013;132(12):2956-66.
2013: Eric Guerin; Shan Man; Ping Xu; Robert S Kerbel
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Cancer research 2013;73(9):2743-8.
2013: Christina Hackl; Shan Man; Chloe Milsom; Ping Xu; Giulio Francia; Robert S Kerbel
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Gut 2013;62(2):259-71.
2012: Robert S Kerbel
Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.
Journal of mammary gland biology and neoplasia 2012;17(3-4):229-39.
2012: William Cruz-Muñoz; Giulio Francia; Maria L Jaramillo; Shan Man; Sherif S Morgan; Andre Nantel; Maureen D O'Connor-McCourt; Ping Xu; Myriam Banville; Catherine Collins; Lee D Cranmer; Robert S Kerbel
Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.
Cancer research 2012;72(19):4909-19.
2012: John R Mackey; Deanna M McLeod; Alexander H G Paterson; Stephen K Chia; Loretta L Collins; Karen A Gelmon; Robert S Kerbel; Daniel Rayson; André Robidoux; Sunil Verma; Kathleen I Pritchard
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.
Cancer treatment reviews 2012;38(6):673-88.
2012: Giacomo Allegrini; Giada Arrighi; Maria Teresa Barletta; Giovanni Brandi; Bastianina Canu; Silvio Chericoni; Andrea Ciarlo; Romano Danesi; Teresa Di Desidero; Antonello Di Paolo; Alfredo Falcone; Anna Fioravanti; Andrea Fontana; Mario Giusiani; Robert S Kerbel; Fotios Loupakis; Sara Lucchesi; Gianluca Masi; Paola Orlandi; Guido Bocci
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Angiogenesis 2012;15(2):275-86.
2012: Giulio Francia; Christina Hackl; Kae Hashimoto; Shan Man; Yuval Shaked; Julie Stewart; John Sun; Mark Uhlik; Ping Xu; Melissa Yin; Carolyn Cesta; Anne H Dantzig; F Stuart Foster; Robert S Kerbel
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Molecular cancer therapeutics 2012;11(3):680-9.
2011: Michael C Schmid; Yuval Shaked; Christie J Avraamides; Philippe Foubert; Sang Won Kang; Robert S Kerbel; Judith A Varner
Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth.
Cancer research 2011;71(22):6965-75.
2011: Robert S Kerbel
Reappraising antiangiogenic therapy for breast cancer.
Breast (Edinburgh, Scotland) 2011;20 Suppl 3():S56-60.
2011: Tali Voloshin; Liat Benayoun; Rotem Bril; Svetlana Gingis-Velitski; Robert S Kerbel; Shan Man; Chloe Milsom; Michal Munster; Yuval Shaked
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
Blood 2011;118(12):3426-35.
2011: Sushil Kumar; Shan Man; Reza Bayat Mokhtari; Indhira Dias Oliveira; Reihaneh Sheikh; Bing Wu; Ping Xu; Herman Yeger; Libo Zhang; Robert S Kerbel; Sylvain Baruchel
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5656-67.
2011: Avital Gaziel-Sovran; Douglas Hanniford; Nina Bhardwaj; Mary K Collins; John F Dankert; Farbod Darvishian; Raffaella Di Micco; Adrian Erlebacher; Robert S Kerbel; Lara K Mahal; Iman Osman; John F Rakus; Miguel F Segura; Shulian Shang; Yongzhao Shao; Eleazar Vega-Saenz de Miera; Jiri Zavadil; Eva Hernando
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.
Cancer cell 2011;20(1):104-18.
2011: John M L Ebos; Robert S Kerbel
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
Nature reviews. Clinical oncology 2011;8(4):210-21.
2011: William Cruz-Muñoz; Robert S Kerbel
Preclinical approaches to study the biology and treatment of brain metastases.
Seminars in cancer biology 2011;21(2):123-30.
2011: Hideki Iwamoto; Takuji Torimura; Toru Nakamura; Osamu Hashimoto; Kinya Inoue; Junichi Kurogi; Takashi Niizeki; Reiichiro Kuwahara; Mitsuhiko Abe; Hiromori Koga; Hirohisa Yano; Robert S Kerbel; Takato Ueno; Michio Sata
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Neoplasia (New York, N.Y.) 2011;13(3):187-97.
2011: Greta Garrido; Ilia A Tikhomirov; Ailem Rabasa; Eric Yang; Elías Gracia; Normando Iznaga-Escobar; Luis E Fernández; Tania Crombet; Robert S Kerbel; Rolando Pérez
Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Cancer biology & therapy 2011;11(4):373-82.
2011: Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Mouse models of advanced spontaneous metastasis for experimental therapeutics.
Nature reviews. Cancer 2011;11(2):135-41.
2011: Urban Emmenegger; Giulio Francia; Annabelle Chow; Yuval Shaked; Andrew Kouri; Shan Man; Robert S Kerbel
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
Neoplasia (New York, N.Y.) 2011;13(1):40-8.
2010: Urban Emmenegger; Robert S Kerbel
Cancer: Chemotherapy counteracted.
Nature 2010;468(7324):637-8.
2010: Terence C Tang; Shan Man; Ping Xu; Giulio Francia; Kae Hashimoto; Urban Emmenegger; Robert S Kerbel
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Neoplasia (New York, N.Y.) 2010;12(11):928-40.
2010: Robert S Kerbel; John M L Ebos
Peering into the aftermath: The inhospitable host?
Nature medicine 2010;16(10):1084-5.
2010: Giulio Francia; Robert S Kerbel
Raising the bar for cancer therapy models.
Nature biotechnology 2010;28(6):561-2.
2010: Marlies H G Langenberg; Maarten W Nijkamp; Jeanine M L Roodhart; Nikol Snoeren; Terence Tang; Yuval Shaked; Richard van Hillegersberg; Petronella O Witteveen; Joost S P Vermaat; Onno Kranenburg; Robert S Kerbel; Rene H Medema; Inne H M Borel Rinkes; Emile E Voest
Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.
Cancer biology & therapy 2010;9(9):743-8.
2010: Kae Hashimoto; Shan Man; Ping Xu; William Cruz-Munoz; Terence Tang; Rakesh Kumar; Robert S Kerbel
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Molecular cancer therapeutics 2010;9(4):996-1006.
2010: Terence C Tang; Shan Man; Christina Lee; Ping Xu; Robert S Kerbel
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Neoplasia (New York, N.Y.) 2010;12(3):264-74.
2010: Urban Emmenegger; Giulio Francia; Yuval Shaked; Robert S Kerbel
Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2010;180():165-83.
2009: Giulio Francia; Shan Man; Chyan-Jang Lee; Christina Lee; Ping Xu; Miriam Mossoba; Urban Emmenegger; Jeffrey A Medin; Robert S Kerbel
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(20):6358-66.
2009: Robert S Kerbel
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer.
Breast (Edinburgh, Scotland) 2009;18 Suppl 3():S41-7.
2009: Laura G Daenen; Yuval Shaked; Shan Man; Ping Xu; Emile E Voest; Robert M Hoffman; David J Chaplin; Robert S Kerbel
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Molecular cancer therapeutics 2009;8(10):2872-81.
2009: Yuval Shaked; Terence Tang; Jill Woloszynek; Laura G Daenen; Shan Man; Ping Xu; Shi-Rong Cai; Jeffrey M Arbeit; Emile E Voest; David J Chaplin; Jon Smythe; Adrian Harris; Paul Nathan; Ian Judson; Gordon Rustin; Francesco Bertolini; Daniel C Link; Robert S Kerbel
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Cancer research 2009;69(19):7524-8.
2009: Chris Folkins; Yuval Shaked; Shan Man; Terence Tang; Christina Lee; Zhenping Zhu; Robert M Hoffman; Robert S Kerbel
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.
Cancer research 2009;69(18):7243-51.
2009: Alicia M Viloria-Petit; Laurent David; Jun Yong Jia; Tuba Erdemir; Anita L Bane; Dushanthi Pinnaduwage; Luba Roncari; Masahiro Narimatsu; Rohit Bose; Jason Moffat; John Wong; Robert S Kerbel; Frances P O'Malley; Irene L Andrulis; Jeffrey L Wrana
A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(33):14028-33.
2009: John M L Ebos; Christina Lee; Robert S Kerbel
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5020-5.
2009: William Cruz-Munoz; Shan Man; Robert S Kerbel
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(15):4867-74.
2009: Francesco Bertolini; Patrizia Mancuso; Paola Braidotti; Yuval Shaked; Robert S Kerbel
The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer.
Biochimica et biophysica acta 2009;1796(1):27-32.
2009: Anthony J Mutsaers; Giulio Francia; Shan Man; Christina Lee; John M L Ebos; Yan Wu; Larry Witte; Scott Berry; Malcolm Moore; Robert S Kerbel
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2397-405.
2009: Khalid Al-Nedawi; Brian Meehan; Robert S Kerbel; Anthony C Allison; Janusz Rak
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(10):3794-9.
2009: John M L Ebos; Christina Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer cell 2009;15(3):232-9.
2009: Giulio Francia; Urban Emmenegger; Robert S Kerbel
Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy.
Cancer cell 2009;15(1):3-5.
2008: Giulio Francia; Urban Emmenegger; Christina Lee; Yuval Shaked; Christopher Folkins; Miriam Mossoba; Jeffrey A Medin; Shan Man; Zhenping Zhu; Larry Witte; Robert S Kerbel
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
Molecular cancer therapeutics 2008;7(10):3452-9.
2008: Yuval Shaked; Erik Henke; Jeanine M L Roodhart; Patrizia Mancuso; Marlies H G Langenberg; Marco Colleoni; Laura G Daenen; Shan Man; Ping Xu; Urban Emmenegger; Terence Tang; Zhenping Zhu; Larry Witte; Robert M Strieter; Francesco Bertolini; Emile E Voest; Robert Benezra; Robert S Kerbel
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Cancer cell 2008;14(3):263-73.
2008: Robert S Kerbel; Robert Benezra; David C Lyden; Koichi Hattori; Beate Heissig; Daniel J Nolan; Vivek Mittal; Yuval Shaked; Sergio Dias; Francesco Bertolini; Shahin Rafii
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(34):E54; author reply E55.
2008: Daniel Voskas; Yael Babichev; Ling S Ling; Jennifer Alami; Yuval Shaked; Robert S Kerbel; Brian Ciruna; Daniel J Dumont
An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice.
Journal of leukocyte biology 2008;84(1):59-67.
2008: William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
Cancer research 2008;68(12):4500-5.
2008: Robert S Kerbel
Tumor angiogenesis.
The New England journal of medicine 2008;358(19):2039-49.
2008: Toshio Kuwai; Toru Nakamura; Takamitsu Sasaki; Sun-Jin Kim; Dominic Fan; Gabriel J Villares; Maya Zigler; Hua Wang; Menashe Bar-Eli; Robert S Kerbel; Isaiah J Fidler
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
Neoplasia (New York, N.Y.) 2008;10(5):489-500.
2008: Fernando Doñate; Graham C Parry; Yuval Shaked; Harvey Hensley; Xiaojun Guan; Ivy Beck; Ziva Tel-Tsur; Marian L Plunkett; Mari Manuia; David E Shaw; Robert S Kerbel; Andrew P Mazar
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(7):2137-44.
2008: Julia L Glade Bender; Peter Charles Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark Krailo; Ashish Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):399-405.
2008: John M L Ebos; Christina Lee; Elena Bogdanovic; Jennifer Alami; Paul Van Slyke; Giulio Francia; Ping Xu; Anthony J Mutsaers; Daniel J Dumont; Robert S Kerbel
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Cancer research 2008;68(2):521-9.
2007: MARTA BOSCH; Hiroaki Okuyama; Jacob B Wesley; KAKALI SARKAR; Hideo Kimura; Ye V Liu; Huafeng Zhang; Marianne Strazza; Sergio Rey; Lindsey Savino; Yi Fu Zhou; Karin R McDonald; Youn Na; Scott Vandiver; Alireza Rabi; Yuval Shaked; Robert S Kerbel; Theresa M Lavallee; Gregg L Semenza
Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia.
Circulation research 2007;101(12):1310-8.
2007: Robert S Kerbel
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
Cancer research and treatment : official journal of Korean Cancer Association 2007;39(4):150-9.
2007: Urban Emmenegger; Robert S Kerbel
Five years of clinical experience with metronomic chemotherapy: achievements and perspectives.
Onkologie 2007;30(12):606-8.
2007: Shan Man; Raquel Munoz; Robert S Kerbel
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Cancer metastasis reviews 2007;26(3-4):737-47.
2007: John M L Ebos; Christina Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(43):17069-74.
2007: Francesco Bertolini; Patrizia Mancuso; Yuval Shaked; Robert S Kerbel
Molecular and cellular biomarkers for angiogenesis in clinical oncology.
Drug discovery today 2007;12(19-20):806-12.
2007: Joshua J Rychak; James Graba; Alison M Y Cheung; Bina S Mystry; Jonathan R Lindner; Robert S Kerbel; F Stuart Foster
Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis.
Molecular imaging 2007;6(5):289-96.
2007: Yuval Shaked; Robert S Kerbel
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
Cancer research 2007;67(15):7055-8.
2007: Urban Emmenegger; Yuval Shaked; Shan Man; Guido Bocci; Ivan Spasojevic; Giulio Francia; Andrew Kouri; Robert Coke; William Cruz-Munoz; Susan M Ludeman; O Michael Colvin; Robert S Kerbel
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
Molecular cancer therapeutics 2007;6(8):2280-9.
2007: Alison M Y Cheung; Allison S Brown; Viviene Cucevic; Marcia Roy; Andrew Needles; Victor Yang; Daniel J Hicklin; Robert S Kerbel; F Stuart Foster
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Ultrasound in medicine & biology 2007;33(8):1259-68.
2007: Fotios Loupakis; Alfredo Falcone; Gianluca Masi; Anna Fioravanti; Robert S Kerbel; Mario Del Tacca; Guido Bocci
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1816-8.
2007: Chris Folkins; Shan Man; Ping Xu; Yuval Shaked; Daniel J Hicklin; Robert S Kerbel
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Cancer research 2007;67(8):3560-4.
2007: Dave Cervi; Yuval Shaked; Mehran Haeri; Tatiana Usenko; Christina Lee; Jody J Haigh; Andras Nagy; Robert S Kerbel; Eitan Yefenof; Yaacov Ben David
Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.
Blood 2007;109(5):2139-46.
2007: Alessia Ciarrocchi; Vlaidmir Jankovic; Yuval Shaked; Daniel J Nolan; Vivek Mittal; Robert S Kerbel; Stephen D Nimer; Robert Benezra
Id1 restrains p21 expression to control endothelial progenitor cell formation.
PloS one 2007;2(12):e1338.
2006: Francesco Bertolini; Yuval Shaked; Patrizia Mancuso; Robert S Kerbel
The multifaceted circulating endothelial cell in cancer: towards marker and target identification.
Nature reviews. Cancer 2006;6(11):835-45.
2006: Yuval Shaked; Alessia Ciarrocchi; Marcela Franco; Christina Lee; Shan Man; Alison M Cheung; Daniel J Hicklin; David Chaplin; F Stuart Foster; Robert Benezra; Robert S Kerbel
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Science (New York, N.Y.) 2006;313(5794):1785-7.
2006: Rena Buckstein; Robert S Kerbel; Yuval Shaked; Rakesh Nayar; Cindy Foden; Ruth Turner; Christina Lee; Diane Taylor; Liying Zhang; Shan Man; Sylvain Baruchel; Diana Stempak; Francesco Bertolini; Michael Crump
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5190-8.
2006: Yuval Shaked; Francesco Bertolini; Urban Emmenegger; Christina Lee; Robert S Kerbel
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):4040; author reply 4040-1.
2006: Sylvia S W Ng; Alex Sparreboom; Yuval Shaked; Christina Lee; Shan Man; Neil Desai; Patrick Soon-Shiong; William D Figg; Robert S Kerbel
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
2006: Patrizia Mancuso; Marco Colleoni; Angelica Calleri; Laura Orlando; Patrick Maisonneuve; Giancarlo Pruneri; Alice Agliano; Aron Goldhirsch; Yuval Shaked; Robert S Kerbel; Francesco Bertolini
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
Blood 2006;108(2):452-9.
2006: Robert S Kerbel
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Science (New York, N.Y.) 2006;312(5777):1171-5.
2006: Marcela Franco; Shan Man; Limor Chen; Urban Emmenegger; Yuval Shaked; Alison M Cheung; Allison S Brown; Daniel J Hicklin; F Stuart Foster; Robert S Kerbel
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Cancer research 2006;66(7):3639-48.
2006: Raquel Munoz; Shan Man; Yuval Shaked; Christina Lee; John Wong; Giulio Francia; Robert S Kerbel
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Cancer research 2006;66(7):3386-91.
2006: Jeanne M du Manoir; Giulio Francia; Shan Man; Miriam Mossoba; Jeffrey A Medin; Alicia Viloria-Petit; Daniel J Hicklin; Urban Emmenegger; Robert S Kerbel
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):904-16.
2006: Urban Emmenegger; Gerard Morton; Giulio Francia; Yuval Shaked; Marcela Franco; Adina Weinerman; Shan Man; Robert S Kerbel
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Cancer research 2006;66(3):1664-74.
2005: Francesco Bertolini; Patrizia Mancuso; Robert S Kerbel
Circulating endothelial progenitor cells.
The New England journal of medicine 2005;353(24):2613-6; author reply 2613-6.
2005: Napoleone Ferrara; Robert S Kerbel
Angiogenesis as a therapeutic target.
Nature 2005;438(7070):967-74.
2005: Raquel Munoz; Yuval Shaked; Francesco Bertolini; Urban Emmenegger; Shan Man; Robert S Kerbel
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
Breast (Edinburgh, Scotland) 2005;14(6):466-79.
2005: Zaiping Liu; Hongbing Li; Mathieu Derouet; Jorge Filmus; Eric C LaCasse; Robert G Korneluk; Robert S Kerbel; Kirill Rosen
ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation.
The Journal of biological chemistry 2005;280(45):37383-92.
2005: Yuval Shaked; Guido Bocci; Raquel Munoz; Shan Man; John M L Ebos; Daniel J Hicklin; Francesco Bertolini; Robert D'Amato; Robert S Kerbel
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.
Current cancer drug targets 2005;5(7):551-9.
2005: Urban Emmenegger; Robert S Kerbel
A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7589-92.
2005: Yuval Shaked; Urban Emmenegger; Shan Man; Dave Cervi; Francesco Bertolini; Yaacov Ben David; Robert S Kerbel
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
Blood 2005;106(9):3058-61.
2005: Giulio Francia; Shane K Green; Guido Bocci; Shan Man; Urban Emmenegger; John M L Ebos; Adina Weinerman; Yuval Shaked; Robert S Kerbel
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.
Molecular cancer therapeutics 2005;4(10):1484-94.
2005: Robert S Kerbel
Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed.
Cancer cell 2005;8(4):269-71.
2005: Ronald L Yap; Dorina Veliceasa; Urban Emmenegger; Robert S Kerbel; Laura M McKay; Jack Henkin; Olga V Volpert
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6678-85.
2005: Yuval Shaked; Urban Emmenegger; Giulio Francia; Limor Chen; Christina Lee; Shan Man; Armen Paraghamian; Yaacov Ben David; Robert S Kerbel
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Cancer research 2005;65(16):7045-51.
2005: Li Ma; Giulio Francia; Alicia Viloria-Petit; Daniel J Hicklin; Jeanne M du Manoir; Janusz Rak; Robert S Kerbel
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Cancer research 2005;65(12):5365-73.
2005: Yuval Shaked; Dave Cervi; Manuela Neuman; Limor Chen; Giannoula Klement; Crystal R Michaud; Mehran Haeri; Brian J Pak; Robert S Kerbel; Yaacov Ben David
The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells.
Blood 2005;105(11):4500-7.
2005: Daniel Voskas; Nina Jones; Paul Van Slyke; Celina Sturk; Wing Chang; Alexandra L Haninec; Yael Olya Babichev; Jennifer Tran; Zubin Master; Stephen Chen; Nicole Ward; Maribelle Cruz; Jamie Jones; Robert S Kerbel; Serge Jothy; Lina Dagnino; Jack Arbiser; Giannoula Klement; Daniel J Dumont
A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
The American journal of pathology 2005;166(3):843-55.
2005: Andrew M Davidoff; Catherine Y C Ng; Youbin Zhang; Christian J Streck; Stephanie J Mabry; Susan H Barton; Troy A Baudino; Junfang Zhou; Robert S Kerbel; Elio F Vanin; Amit C Nathwani
Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(2):300-10.
2005: Hideaki Watanabe; Adam J Mamelak; Elliot Weiss; Binghe Wang; Irwin Freed; Angela K Brice; Lynn M Wachtman; Kathleen L Gabrielson; Naoko Yokota; Daniel J Hicklin; Robert S Kerbel; Mark Haas; Daniel N Sauder
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):407-9.
2005: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Cancer cell 2005;7(1):101-11.
2004: Hideaki Watanabe; Adam J Mamelak; Binghe Wang; Brandon G Howell; Irwin Freed; Clemens Esche; Masashi Nakayama; Go Nagasaki; Daniel J Hicklin; Robert S Kerbel; Daniel N Sauder
Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity.
Experimental dermatology 2004;13(11):671-81.
2004: Robert S Kerbel
Vasohibin: the feedback on a new inhibitor of angiogenesis.
The Journal of clinical investigation 2004;114(7):884-6.
2004: Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Cancer research 2004;64(18):6616-25.
2004: Giulio Francia; Shan Man; Beverly Teicher; Luigi Grasso; Robert S Kerbel
Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.
Molecular and cellular biology 2004;24(15):6837-49.
2004: John M L Ebos; Guido Bocci; Shan Man; Philip E Thorpe; Daniel J Hicklin; Danielle Zhou; Xiaohong Jia; Robert S Kerbel
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Molecular cancer research : MCR 2004;2(6):315-26.
2004: George Vande Woude; Gary J Kelloff; Raymond W Ruddon; Han-Mo Koo; Caroline C Sigman; J Carl Barrett; Robert W Day; Adam Dicker; Robert S Kerbel; David R Parkinson; William J Slichenmyer
Reanalysis of cancer drugs: old drugs, new tricks.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3897-907.
2004: John W Park; Robert S Kerbel; Gary J Kelloff; J Carl Barrett; Bruce A Chabner; David R Parkinson; Jonathan Peck; Raymond W Ruddon; Caroline C Sigman; Dennis J Slamon
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3885-96.
2004: Gary J Kelloff; Robert C Bast; Donald S Coffey; Anthony V D'Amico; Robert S Kerbel; John W Park; Raymond W Ruddon; Gordon J S Rustin; Richard L Schilsky; Caroline C Sigman; George Vande Woude
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3881-4.
2004: Urban Emmenegger; Shan Man; Yuval Shaked; Giulio Francia; John Wong; Daniel J Hicklin; Robert S Kerbel
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Cancer research 2004;64(11):3994-4000.
2004: Robert S Kerbel; Barton A. Kamen
The anti-angiogenic basis of metronomic chemotherapy.
Nature reviews. Cancer 2004;4(6):423-36.
2004: Peng-Sheng Zheng; Jianping Wen; Lee Cyn Ang; Wang Sheng; Alicia Viloria-Petit; Yelina Wang; Yaojiong Wu; Robert S Kerbel; Burton B Yang
Versican/PG-M G3 domain promotes tumor growth and angiogenesis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(6):754-6.
2004: Alicia M Viloria-Petit; Robert S Kerbel
Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.
International journal of radiation oncology, biology, physics 2004;58(3):914-26.
2004: Shane K Green; Giulio Francia; Ciro Isidoro; Robert S Kerbel
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
Molecular cancer therapeutics 2004;3(2):149-59.
2004: Robert S Kerbel
Antiangiogenic drugs and current strategies for the treatment of lung cancer.
Seminars in oncology 2004;31(1 Suppl 1):54-60.
2004: Brian J Pak; Jane Lee; Boun L Thai; Serge Y Fuchs; Yuval Shaked; Ze'ev Ronai; Robert S Kerbel; Yaacov Ben David
Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase.
Oncogene 2004;23(1):30-8.
2003: Benjamin Gesundheit; Giannoula Klement; Christof Senger; Robert S Kerbel; Mark W Kieran; Sylvain Baruchel; Laurence Becker
Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood.
Medical and pediatric oncology 2003;41(6):516-26.
2003: Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(22):12917-22.
2003: L Michael Glode; Albaha Barqawi; Frances Crighton; E David Crawford; Robert S Kerbel
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Cancer 2003;98(8):1643-8.
2003: Guido Bocci; Romano Danesi; Mario Del Tacca; Robert S Kerbel
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor.
European journal of pharmacology 2003;477(1):17-21.
2003: Alicia Viloria-Petit; Lucile Miquerol; Joanne L Yu; Marina Gertsenstein; Capucine Sheehan; Linda May; Jack Henkin; Corrinne G Lobe; Andras Nagy; Robert S Kerbel; Janusz Rak
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.
The EMBO journal 2003;22(16):4091-102.
2003: Zubin Master; Jennifer Tran; Aseem Bishnoi; Stephen H Chen; John M L Ebos; Paul Van Slyke; Robert S Kerbel; Daniel J Dumont
Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization.
The Journal of biological chemistry 2003;278(32):30170-9.
2003: Francesco Bertolini; Saki Paul; Patrizia Mancuso; Silvia Monestiroli; Alberto Gobbi; Yuval Shaked; Robert S Kerbel
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
Cancer research 2003;63(15):4342-6.
2003: Robert S Kerbel
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
Cancer biology & therapy 2003;2(4 Suppl 1):S134-9.
2003: Harry Bartelink; Christopher Benz; Don Cleveland; Ronald Dorn; Julie R Gralow; William J Gradishar; Kathleen Grant; Ruth Heimann; Samuel Hellman; Clifford Hudis; Robert S Kerbel; Marc Lippman; John Lung; Mitchell C Posner; Patricia Steeg; Robert Vestal; Ralph R Weichselbaum; Bruce R Zetter
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003.
Breast cancer research and treatment 2003;80(2):139-44.
2003: Nina Jones; Stephen H Chen; Celina Sturk; Zubin Master; Jennifer Tran; Robert S Kerbel; Daniel J Dumont
A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function.
Molecular and cellular biology 2003;23(8):2658-68.
2003: Stephen Gately; Robert S Kerbel
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Progress in experimental tumor research 2003;37():179-92.
2003: Robert S Kerbel
Some guidelines for building a successful career in cancer research.
Cancer biology & therapy 2003;2(1):111-4.
2003: David E Goertz; Joanne L Yu; Robert S Kerbel; Peter N Burns; F Stuart Foster
High-frequency 3-D color-flow imaging of the microcirculation.
Ultrasound in medicine & biology 2003;29(1):39-51.
2002: John M L Ebos; Jennifer Tran; Zubin Master; Daniel J Dumont; Junia V Melo; Elisabeth Buchdunger; Robert S Kerbel
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Molecular cancer research : MCR 2002;1(2):89-95.
2002: Guido Bocci; K C Nicolaou; Robert S Kerbel
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
Cancer research 2002;62(23):6938-43.
2002: Shane K Green; Mikael C I Karlsson; Jeffrey V Ravetch; Robert S Kerbel
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
Cancer research 2002;62(23):6891-900.
2002: David E Goertz; Joanne L Yu; Robert S Kerbel; Peter N Burns; F Stuart Foster
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow.
Cancer research 2002;62(22):6371-5.
2002: Robert S Kerbel; Judah Folkman
Clinical translation of angiogenesis inhibitors.
Nature reviews. Cancer 2002;2(10):727-39.
2002: Shan Man; Guido Bocci; Giulio Francia; Shane K Green; Serge Jothy; Douglas Hanahan; Peter Bohlen; Daniel J Hicklin; Gabriele Bergers; Robert S Kerbel
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Cancer research 2002;62(10):2731-5.
2002: Jennifer Tran; Zubin Master; Joanne L Yu; Janusz Rak; Daniel J Dumont; Robert S Kerbel
A role for survivin in chemoresistance of endothelial cells mediated by VEGF.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(7):4349-54.
2002: Janusz Rak; Joanne L Yu; Robert S Kerbel; Brenda L Coomber
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
Cancer research 2002;62(7):1931-4.
2002: Joanne L Yu; Janusz Rak; Giannoula Klement; Robert S Kerbel
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts.
Cancer research 2002;62(6):1838-46.
2002: Joanne L Yu; Janusz Rak; Brenda L Coomber; Daniel J Hicklin; Robert S Kerbel
Effect of p53 status on tumor response to antiangiogenic therapy.
Science (New York, N.Y.) 2002;295(5559):1526-8.
2002: Giannoula Klement; Ping Huang; Barbara Mayer; Shane K Green; Shan Man; Peter Bohlen; Daniel J Hicklin; Robert S Kerbel
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):221-32.
2001: Zubin Master; Nina Jones; Jennifer Tran; Jamie Jones; Robert S Kerbel; Daniel J Dumont
Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak.
The EMBO journal 2001;20(21):5919-28.
2001: B Mayer; Giannoula Klement; M Kaneko; Shan Man; Serge Jothy; Janusz Rak; Robert S Kerbel
Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas.
Gastroenterology 2001;121(4):839-52.
2001: Robert S Kerbel
Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18 Suppl):45S-51S.
2001: Alicia Viloria-Petit; T Crombet; Serge Jothy; Daniel J Hicklin; Peter Bohlen; J M Schlaeppi; Janusz Rak; Robert S Kerbel
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Cancer research 2001;61(13):5090-101.
2001: A Frankel; Kirill Rosen; Jorge Filmus; Robert S Kerbel
Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
Cancer research 2001;61(12):4837-41.
2001: Robert S Kerbel; J Yu; Jennifer Tran; Shan Man; Alicia Viloria-Petit; Giannoula Klement; Brenda L Coomber; Janusz Rak
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
Cancer metastasis reviews 2001;20(1-2):79-86.
2001: Brian J Pak; W Chu; Shijiang Lu; Robert S Kerbel; Yaacov Ben David
Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2.
Cancer metastasis reviews 2001;20(1-2):27-32.
2000: Janusz Rak; Joanne L Yu; Giannoula Klement; Robert S Kerbel
Oncogenes and angiogenesis: signaling three-dimensional tumor growth.
The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research 2000;5(1):24-33.
2000: Brian J Pak; Q Li; Robert S Kerbel; Yaacov Ben David
TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content.
Melanoma research 2000;10(5):499-505.
2000: O López-Ocejo; Alicia Viloria-Petit; M Bequet-Romero; Debabrata Mukhopadhyay; Janusz Rak; Robert S Kerbel
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
Oncogene 2000;19(40):4611-20.
2000: Robert S Kerbel; Alicia Viloria-Petit; Giannoula Klement; Janusz Rak
'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
European journal of cancer (Oxford, England : 1990) 2000;36(10):1248-57.
2000: Kirill Rosen; Janusz Rak; T Leung; Nicholas Dean; Robert S Kerbel; Jorge Filmus
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells.
The Journal of cell biology 2000;149(2):447-56.
2000: Giannoula Klement; Sylvain Baruchel; Janusz Rak; Shan Man; K Clark; Daniel J Hicklin; Peter Bohlen; Robert S Kerbel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
The Journal of clinical investigation 2000;105(8):R15-24.
2000: W Chu; Brian J Pak; MR Bani; M Kapoor; Shijiang Lu; Ami Tamir; Robert S Kerbel; Yaacov Ben David
Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
Oncogene 2000;19(3):395-402.
2000: Janusz Rak; Y Mitsuhashi; C Sheehan; Ami Tamir; Alicia Viloria-Petit; Jorge Filmus; S J Mansour; N G Ahn; Robert S Kerbel
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.
Cancer research 2000;60(2):490-8.
2000: David E Goertz; DA Christopher; Joanne L Yu; Robert S Kerbel; Peter N Burns; F Stuart Foster
High-frequency color flow imaging of the microcirculation.
Ultrasound in medicine & biology 2000;26(1):63-71.
1999: J Tran; Janusz Rak; C Sheehan; S D Saibil; Eric C LaCasse; Robert G Korneluk; Robert S Kerbel
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.
Biochemical and biophysical research communications 1999;264(3):781-8.
1999: J K Krestow; Janusz Rak; Jorge Filmus; Robert S Kerbel
Functional dissociation of anoikis-like cell death and activity of stress activated protein kinase.
Biochemical and biophysical research communications 1999;260(1):48-53.
1999: John MacDougall; M R Bani; Y Lin; R J Muschel; Robert S Kerbel
'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression.
British journal of cancer 1999;80(3-4):504-12.
1999: S K Green; A Frankel; Robert S Kerbel
Adhesion-dependent multicellular drug resistance.
Anti-cancer drug design 1999;14(2):153-68.
1999: Vivi Ann Flørenes; C Lu; N Bhattacharya; Janusz Rak; C Sheehan; Joyce M Slingerland; Robert S Kerbel
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.
Oncogene 1999;18(4):1023-32.
1998: Kirill Rosen; Janusz Rak; J Jin; Robert S Kerbel; M J Newman; Jorge Filmus
Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells.
Current biology : CB 1998;8(24):1331-4.
1998: B Lieubeau-Teillet; Janusz Rak; Serge Jothy; O Iliopoulos; William G Kaelin; Robert S Kerbel
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Cancer research 1998;58(21):4957-62.
1998: B St Croix; C Sheehan; Janusz Rak; Vivi Ann Flørenes; Joyce M Slingerland; Robert S Kerbel
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).
The Journal of cell biology 1998;142(2):557-71.
1998: Vivi Ann Flørenes; Gunhild M Maelandsmo; Robert S Kerbel; Joyce M Slingerland; J M Nesland; R Holm
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
The American journal of pathology 1998;153(1):305-12.
1998: Robert S Kerbel; Alicia Viloria-Petit; F Okada; Janusz Rak
Establishing a link between oncogenes and tumor angiogenesis.
Molecular medicine (Cambridge, Mass.) 1998;4(5):286-95.
1998: F Okada; Janusz Rak; B S Croix; B Lieubeau; M Kaya; L Roncari; S Shirasawa; T Sasazuki; Robert S Kerbel
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(7):3609-14.
1998: Robert S Kerbel
What is the optimal rodent model for anti-tumor drug testing?
Cancer metastasis reviews 1998;17(3):301-4.
1997: A M Petit; Janusz Rak; M C Hung; P Rockwell; N Goldstein; B Fendly; Robert S Kerbel
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
The American journal of pathology 1997;151(6):1523-30.
1997: B St Croix; Robert S Kerbel
Cell adhesion and drug resistance in cancer.
Current opinion in oncology 1997;9(6):549-56.
1997: A Frankel; R Buckman; Robert S Kerbel
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Cancer research 1997;57(12):2388-93.
1996: Vivi Ann Flørenes; N Bhattacharya; M R Bani; Yaacov Ben David; Robert S Kerbel; Joyce M Slingerland
TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1.
Oncogene 1996;13(11):2447-57.
1996: Robert S Kerbel; B St Croix; V A Florenes; Janusz Rak
Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors.
Human cell 1996;9(4):257-64.
1996: Janusz Rak; Jorge Filmus; Robert S Kerbel
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis.
European journal of cancer (Oxford, England : 1990) 1996;32A(14):2438-50.
1996: Gunhild M Maelandsmo; Ruth Holm; Oystein Fodstad; Robert S Kerbel; Vivi Ann Flørenes
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
The American journal of pathology 1996;149(6):1813-22.
1996: B St Croix; Vivi Ann Flørenes; Janusz Rak; M Flanagan; N Bhattacharya; Joyce M Slingerland; Robert S Kerbel
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
Nature medicine 1996;2(11):1204-10.
1996: B S Croix; Janusz Rak; S Kapitain; C Sheehan; C H Graham; Robert S Kerbel
Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.
Journal of the National Cancer Institute 1996;88(18):1285-96.
1996: C Lu; C Sheehan; Janusz Rak; C A Chambers; N Hozumi; Robert S Kerbel
Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1417-25.
1996: M R Bani; Janusz Rak; D Adachi; R Wiltshire; Jeffrey M. Trent; Robert S Kerbel; Yaacov Ben David
Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype.
Cancer research 1996;56(13):3075-86.
1995: Janusz Rak; Jorge Filmus; G Finkenzeller; S Grugel; Dieter Marmé; Robert S Kerbel
Oncogenes as inducers of tumor angiogenesis.
Cancer metastasis reviews 1995;14(4):263-77.
1995: Robert S Kerbel
Significance of tumor-host interactions in cancer growth and metastases.
Cancer metastasis reviews 1995;14(4):259-62.
1995: Janusz Rak; Y Mitsuhashi; V Erdos; S N Huang; Jorge Filmus; Robert S Kerbel
Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression.
The Journal of cell biology 1995;131(6 Pt 1):1587-98.
1995: Janusz Rak; Y Mitsuhashi; L Bayko; Jorge Filmus; S Shirasawa; T Sasazuki; Robert S Kerbel
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
Cancer research 1995;55(20):4575-80.
1995: John MacDougall; M R Bani; Y Lin; Janusz Rak; Robert S Kerbel
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.
Cancer research 1995;55(18):4174-81.
1995: John MacDougall; Robert S Kerbel
Constitutive production of 92-kDa gelatinase B can be suppressed by alterations in cell shape.
Experimental cell research 1995;218(2):508-15.
1995: D Paglia; A Oran; C Lu; Robert S Kerbel; Daniel N Sauder; Roddie C McKenzie
Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(5):455-60.
1995: Shijiang Lu; S Man; M R Bani; D Adachi; Robert G Hawley; Robert S Kerbel; Yaacov Ben David
Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance.
Cancer research 1995;55(5):1139-45.
1995: J W Rak; B D St Croix; Robert S Kerbel
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.
Anti-cancer drugs 1995;6(1):3-18.
1994: Charles H Graham; I Connelly; John MacDougall; Robert S Kerbel; William Stetler-Stevenson; Peeyush K Lala
Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta.
Experimental cell research 1994;214(1):93-9.
1994: Charles H Graham; J Rivers; Robert S Kerbel; K S Stankiewicz; W L White
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas.
The American journal of pathology 1994;145(3):510-4.
1994: Charles H Graham; H Kobayashi; K S Stankiewicz; S Man; S J Kapitain; Robert S Kerbel
Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.
Journal of the National Cancer Institute 1994;86(13):975-82.
1994: J W Rak; E J Hegmann; C Lu; Robert S Kerbel
Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression.
Journal of cellular physiology 1994;159(2):245-55.
1994: H Kobayashi; S Man; John MacDougall; Charles H Graham; C Lu; Robert S Kerbel
Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype.
The American journal of pathology 1994;144(4):776-86.
1994: C Lu; Robert S Kerbel
Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma.
Current opinion in oncology 1994;6(2):212-20.
1994: Robert S Kerbel; Janusz Rak; H Kobayashi; M S Man; B St Croix; Charles H Graham
Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors.
Cold Spring Harbor symposia on quantitative biology 1994;59():661-72.
1993: Dan Theodorescu; K M Connors; A Groce; R M Hoffman; Robert S Kerbel
Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions.
Anticancer research 1993;13(4):941-6.
1993: C Lu; Janusz Rak; H Kobayashi; Robert S Kerbel
Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
Cancer research 1993;53(12):2708-11.
1993: Charles H Graham; TS Hawley; Robert G Hawley; John MacDougall; Robert S Kerbel; N Khoo; Peeyush K Lala
Establishment and characterization of first trimester human trophoblast cells with extended lifespan.
Experimental cell research 1993;206(2):204-11.
1993: H Kobayashi; S Man; Charles H Graham; S J Kapitain; B A Teicher; Robert S Kerbel
Acquired multicellular-mediated resistance to alkylating agents in cancer.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(8):3294-8.
1993: C Lu; Robert S Kerbel
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.
The Journal of cell biology 1993;120(5):1281-8.
1993: Jorge Filmus; Robert S Kerbel
Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression.
Current opinion in oncology 1993;5(1):123-9.
1992: E J Hegmann; H C Bauer; Robert S Kerbel
Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells.
Cancer research 1992;52(24):6969-75.
1992: C Lu; M F Vickers; Robert S Kerbel
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(19):9215-9.
1992: Robert S Kerbel
Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm.
The American journal of pathology 1992;141(3):519-24.
1991: Robert S Kerbel; I Cornil; Dan Theodorescu
Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis.
Cancer metastasis reviews 1991;10(3):201-15.
1991: Dan Theodorescu; M Caltabiano; R Greig; David J Rieman; Robert S Kerbel
Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo.
Journal of cellular physiology 1991;148(3):380-90.
1991: Dan Theodorescu; I Cornil; C Sheehan; M S Man; Robert S Kerbel
Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells.
Cancer research 1991;51(16):4486-91.
1991: I Cornil; Dan Theodorescu; S Man; M Herlyn; J Jambrosic; Robert S Kerbel
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(14):6028-32.
1991: B Korczak; Robert S Kerbel; James W Dennis
Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases, transin, and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1991;2(7):335-41.
1991: B Korczak; Robert S Kerbel; J Dennis
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
International journal of cancer. Journal international du cancer 1991;48(4):557-61.
1991: I Cornil; Dan Theodorescu; Robert S Kerbel; M F Poupon
[Metastatic dissemination of cancer cells].
Pathologie-biologie 1991;39(4):300-7.
1991: K S Worton; Robert S Kerbel; Irene L Andrulis
Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate.
Cancer research 1991;51(3):985-9.
1991: Dan Theodorescu; I Cornil; C Sheehan; S Man; Robert S Kerbel
Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread.
International journal of cancer. Journal international du cancer 1991;47(1):118-23.
1991: Dan Theodorescu; D Bergsma; M S Man; N Elshourbagy; C Sheehan; David J Rieman; Robert S Kerbel
Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects.
Growth factors (Chur, Switzerland) 1991;5(4):305-16.
1990: Dan Theodorescu; I Cornil; B J Fernandez; Robert S Kerbel
Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):9047-51.
1990: I Cornil; Robert S Kerbel; James W Dennis
Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization.
The Journal of cell biology 1990;111(2):773-81.
1990: S Yagel; Robert S Kerbel; Peeyush K Lala; T Eldar-Gera; James W Dennis
Basement membrane invasion by first trimester human trophoblast: requirement for branched complex-type Asn-linked oligosaccharides.
Clinical & experimental metastasis 1990;8(4):305-17.
1989: Robert S Kerbel; I Cornil; B Korczak
New insights into the evolutionary growth of tumors revealed by Southern gel analysis of tumors genetically tagged with plasmid or proviral DNA insertions.
Journal of cell science 1989;94 ( Pt 3)():381-7.
1989: I Cornil; S Man; B Fernandez; Robert S Kerbel
Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice.
Journal of the National Cancer Institute 1989;81(12):938-44.
1989: B Korczak; C Whale; Robert S Kerbel
Possible involvement of Ca2+ mobilization and protein kinase C activation in the induction of spontaneous metastasis by mouse mammary adenocarcinoma cells.
Cancer research 1989;49(10):2597-602.
1989: D A Carlow; Robert S Kerbel; Bruce E Elliott
Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma.
Journal of the National Cancer Institute 1989;81(10):759-67.
1989: M Ishikawa; Robert S Kerbel
Characterization of a metastasis-deficient lectin-resistant human melanoma mutant.
International journal of cancer. Journal international du cancer 1989;43(1):134-9.
1988: C Waghorne; M Thomas; A Lagarde; Robert S Kerbel; M L Breitman
Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations.
Cancer research 1988;48(21):6109-14.
1988: M Ishikawa; B Fernandez; Robert S Kerbel
Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain.
Cancer research 1988;48(17):4897-903.
1988: B Korczak; I B Robson; C Lamarche; alan bernstein; Robert S Kerbel
Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo.
Molecular and cellular biology 1988;8(8):3143-9.
1988: E Alvarez; Bruce E Elliott; Alan N Houghton; Robert S Kerbel
Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications.
Cancer research 1988;48(9):2440-5.
1988: M Ishikawa; J W Dennis; S Man; Robert S Kerbel
Isolation and characterization of spontaneous wheat germ agglutinin-resistant human melanoma mutants displaying remarkably different metastatic profiles in nude mice.
Cancer research 1988;48(3):665-70.
1988: Robert S Kerbel; C Waghorne; B Korczak; A Lagarde; M L Breitman
Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications.
Cancer surveys 1988;7(4):597-629.
1988: Robert S Kerbel; C Waghorne; B Korczak; M L Breitman
Clonal changes in tumours during growth and progression evaluated by southern gel analysis of random integrations of foreign DNA.
Ciba Foundation symposium 1988;141():123-48.
1988: C Waghorne; B Korczak; M L Breitman; Robert S Kerbel
Analysis of growth, selection, and metastasis of tumor cell populations in vivo using random insertions of foreign DNA as genetic tags.
Advances in experimental medicine and biology 1988;233():27-37.
1987: C Waghorne; Robert S Kerbel; M L Breitman
Metastatic potential of SP1 mouse mammary adenocarcinoma cells is differentially induced by activated and normal forms of c-H-ras.
Oncogene 1987;1(2):149-55.
1987: Robert S Kerbel; C Waghorne; M S Man; B Elliott; M L Breitman
Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(5):1263-7.
1985: D A Carlow; Robert S Kerbel; J T Feltis; Bruce E Elliott
Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma.
Journal of the National Cancer Institute 1985;75(2):291-301.
1984: Robert S Kerbel; P Frost; R Liteplo; D A Carlow; Bruce E Elliott
Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment.
Journal of cellular physiology. Supplement 1984;3():87-97.